The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between vascular patterns of clear cell renal cell carcinoma and immune cell infiltration and therapeutic response.
 
Marieta Toma
Honoraria - Gilead Sciences
 
Tim Kempchen
No Relationships to Disclose
 
Yangping Li
No Relationships to Disclose
 
Katharina Baschun
No Relationships to Disclose
 
Fabian Hörst
No Relationships to Disclose
 
Melina Kehl
No Relationships to Disclose
 
Niklas Klümper
Stock and Other Ownership Interests - Bicycle Therapeutics; Daiichi Sankyo/UCB Japan; immatics; Pfizer
Honoraria - Astellas Pharma; MSD Oncology
Consulting or Advisory Role - Astellas Pharma; Eisai; MSD Oncology
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Photocure
 
Joerg Ellinger
No Relationships to Disclose
 
Manuel Ritter
Honoraria - Janssen Oncology; Medac; Medac
Research Funding - Procept Biorobotics (Inst)
Travel, Accommodations, Expenses - Medac
 
Kati Erdmann
No Relationships to Disclose
 
Arndt Hartmann
Honoraria - Abbvie; AstraZeneca; BMS; Boehringer Ingelheim; Ipsen; Janssen-Cilag; MSD; Roche
Consulting or Advisory Role - 3DHISTECH; AstraZeneca; Bristol-Myers Squibb; Cepheid; Diaceutics; Illumina; Ipsen; Janssen-Cilag; MSD; NanoString Technologies; Qiagen; Roche
Research Funding - AstraZeneca; BioNTech; Cepheid; Janssen-Cilag; NanoString Technologies; Owkin (Inst); Phäon (Inst); Roche
Expert Testimony - NanoString Technologies
 
Glen Kristiansen
No Relationships to Disclose
 
Thomas Pinetz
Stock and Other Ownership Interests - Relios.Vision GmbH
Patents, Royalties, Other Intellectual Property - Relios.Vision GmbH
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genmab; MSD
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; PCI Biotech; Pfizer; Synthekine
Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Merck Serono; Pfizer
 
Alexander Effland
Stock and Other Ownership Interests - Relios.Vision GmbH
Research Funding - Hyperfine
Patents, Royalties, Other Intellectual Property - Relios.Vision GmbH
 
Michael Hölzel
Stock and Other Ownership Interests - Bicycle Therapeutics; Daiichi Sankyo/UCB Japan; immatics
Honoraria - Biotex/Oncomagnetix; Bristol-Myers Squibb/Roche; Novartis; TME Pharma
Consulting or Advisory Role - BioTex / Oncomagnetics; Novartis; TME Pharma
Research Funding - TME Pharma
Patents, Royalties, Other Intellectual Property - EP 23 000 076.2 and EP 23 000 075.4 patent applications related to biomarkers for NOX-A12 therapy.
Travel, Accommodations, Expenses - TME Pharma